Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
GlaxoSmithKline ( (GB:GSK) ) has shared an announcement.
GSK announced that its new drug applications for depemokimab have been accepted for review in China and Japan for the treatment of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing schedule, offering significant benefits in terms of patient adherence and health system efficiency. This follows positive results from the SWIFT and ANCHOR trials, which demonstrated the drug’s efficacy in reducing exacerbations and nasal polyp size. The acceptance of these applications could strengthen GSK’s position in the respiratory market, providing a new treatment option for conditions driven by type 2 inflammation.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on advancing respiratory medicine. With a significant portfolio of vaccines, targeted biologics, and inhaled medicines, GSK aims to improve outcomes for patients with respiratory diseases such as asthma and COPD, as well as less understood diseases like refractory chronic cough and rarer conditions like systemic sclerosis with interstitial lung disease.
YTD Price Performance: 4.12%
Average Trading Volume: 7,959,773
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £55.35B
See more data about GSK stock on TipRanks’ Stock Analysis page.
